Published: · Last reviewed:
What GLP-1 Does Medicaid Cover? 2026 Drug-by-Diagnosis Guide
Medicaid generally must cover GLP-1 medications prescribed for type 2 diabetes — including Ozempic, Mounjaro, and Rybelsus — when plan rules are met, though prior authorization can still apply. GLP-1s for weight loss alone, like Wegovy and Zepbound, are optional: only 13 state Medicaid programs covered them for obesity as of January 2026 (KFF).
So if you've been asking what GLP-1 does Medicaid cover, the honest answer isn't a simple yes or no — it depends on why the medicine is prescribed. And there's often a stronger coverage path nobody's told you about. We'll show you how to find yours, what to ask, and what to do if you've already been denied.
This guide is for you if…
- You have Medicaid and want to know which GLP-1 it might cover for you
- Your doctor prescribed Ozempic, Wegovy, Zepbound, Mounjaro, Rybelsus, or another GLP-1
- Your pharmacy said you need a “prior authorization”
- You got denied and don't know what to ask next
This guide is not for you if…
- You have private or job-based insurance — see our other GLP-1 insurance guides
- You're shopping for a cash-pay compounded GLP-1 and don't plan to use Medicaid at all
- You just want a coupon — we'll be straight with you below about why coupons usually don't help Medicaid members
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. The right GLP-1 path isn't the same for everyone — it depends on your state, your Medicaid plan and its drug list, whether you want an FDA-approved or compounded medication, and your budget.
Your state, your diagnosis, your plan — about 60 seconds
What GLP-1 does Medicaid cover, by diagnosis?
The short version: Medicaid follows the reason a GLP-1 is prescribed, not just the brand name. Drugs approved for type 2 diabetes have a required coverage path in every state when plan rules are met. Drugs approved only for weight loss are optional and depend on your state. And some drugs have a second FDA-approved use — like heart disease or sleep apnea — that creates a required coverage path nationwide when the diagnosis and prior approval are in place.
That one idea is why two people can ask for the same drug and get two different answers. It's also the single most useful thing on this page. Here's the whole landscape in one table.
| Your situation | GLP-1s Medicaid may cover | The coverage rule | What usually blocks it | Best next step |
|---|---|---|---|---|
| Type 2 diabetes | Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza | Required coverage path when plan rules are met. Plans can still use preferred-drug lists, prior authorization, quantity limits, and step therapy. | No diabetes diagnosis on file, missing labs (like A1C), drug isn't “preferred,” step therapy required | Ask your prescriber to submit the prior authorization with your diabetes diagnosis and A1C. |
| Weight loss / obesity only (adult 21+) | Wegovy, Zepbound, Saxenda, the Wegovy pill, Foundayo (state-specific) | Optional. Federal law lets states skip weight-loss drugs. Only 13 states covered GLP-1s for obesity as of Jan 2026 (KFF). | State excludes weight-loss drugs, BMI rule not met, paperwork incomplete | Check your state first (see the 50-state tracker), then call your plan. |
| Established heart disease + overweight/obesity | Wegovy (and the Wegovy pill) | Required coverage path in every state when documented. FDA approved Wegovy (March 2024) to lower heart-attack, stroke, and heart-death risk in adults with established cardiovascular disease who are overweight or obese. | Request sent as “weight loss only,” missing heart-disease diagnosis | Ask whether the request should go in under the cardiovascular risk reduction use. |
| Moderate-to-severe sleep apnea + obesity | Zepbound | Required coverage path in every state when documented. FDA approved Zepbound (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. | No sleep-study record, apnea not coded, request sent as weight loss | Ask your prescriber to include the sleep apnea diagnosis and sleep-study results. |
| MASH (serious liver disease) with moderate-to-advanced scarring | Wegovy | FDA-approved use; verify your plan's rules. FDA approved Wegovy (2025) for adults with MASH and moderate-to-advanced fibrosis (accelerated approval). | No liver diagnosis or fibrosis evidence on file | Ask your liver specialist to submit under the MASH use. |
| Under age 21 | Depends on diagnosis and medical need | Often required when medically necessary under Medicaid's EPSDT benefit (a federal rule covering medically necessary care for kids and teens). | Adult rules wrongly applied; medical need not documented | Ask the prescriber to cite EPSDT medical necessity with age-specific records. |
| Prediabetes only | Usually not enough on its own | No FDA-approved weight-loss or diabetes use is met by “prediabetes” alone in most plans. | Treated as weight loss / off-label | Ask your clinician if another documented condition changes the path. Don't assume prediabetes equals diabetes. |
| PCOS or insulin resistance only | Usually not enough on its own | Clinically real, but often not a Medicaid coverage reason by itself. | Treated as weight loss / off-label | Ask which diagnosis is actually being used, and whether your state covers obesity drugs. |
| Compounded semaglutide/tirzepatide from a telehealth site | Not a Medicaid path | Compounded drugs are not FDA-approved. The FDA does not verify them for safety, effectiveness, or quality before they're sold. | Medicaid won't treat a cash-pay compounded product like a covered FDA-approved drug | Keep this separate from Medicaid. If weighing cash-pay options, read the cash-pay section below first. |
Note: older exenatide products Byetta and Bydureon BCise were discontinued in the U.S. in 2024. If you see them on an old state document, ask your plan which currently available GLP-1 is preferred.
Read that table once more if you skim nothing else.
If your GLP-1 is for diabetes, you likely have a covered path. If it's for weight loss alone, it depends on your state. And if you have heart disease or sleep apnea, you may have a covered path you didn't know existed.
Your state, your diagnosis, your plan — before your next appointment
Coverage is not the same as medical clearance.
Even if Medicaid has a coverage path for you, your prescriber still has to decide whether a GLP-1 is medically right for you. FDA labels list contraindications and warnings, and you should never start, stop, or switch a medication based on coverage alone. Talk to your clinician first.
A quick, honest admission before we go deeper
Here's something most affiliate sites won't tell you — and we'd rather lose your click than mislead you.
Most GLP-1 telehealth comparison pages, including some of ours, are not your first stop if you have Medicaid. Medicaid coverage runs through your state plan, your plan's drug list, and your doctor's prior authorization — not a cash-pay telehealth checkout. Several popular telehealth companies don't even accept Medicaid patients.
Because we're skipping the hard sell, we can do something more useful: walk you through the path that actually works on Medicaid — your diagnosis, your state, your plan, your appeal rights — and only talk about paying cash at the very end, for the people who truly need it.
Does Medicaid cover GLP-1s for type 2 diabetes?
Generally, yes — in every state. Medicaid generally must cover a participating drugmaker's FDA-approved medicines for their approved uses, and GLP-1s approved for type 2 diabetes qualify (KFF). You may still face prior authorization or be asked to try a “preferred” drug first, but a covered path exists.
| Drug | Active ingredient | Common Medicaid use | The coverage question to ask |
|---|---|---|---|
| Ozempic | semaglutide | Type 2 diabetes | Is Ozempic "preferred" on my state's drug list, or do I try another GLP-1 first? |
| Mounjaro | tirzepatide | Type 2 diabetes | Does my plan require step therapy before Mounjaro? |
| Rybelsus | semaglutide (pill) | Type 2 diabetes | Is oral semaglutide on my formulary? |
| Trulicity | dulaglutide | Type 2 diabetes | Is it required before Ozempic or Mounjaro? |
| Victoza | liraglutide | Type 2 diabetes | Does my plan want the generic or the brand? |
The part that trips people up
Ozempic for diabetes is a different question than Ozempic for weight loss. Same drug, same pen. But if your chart shows only obesity, prediabetes, or PCOS, a plan that would cover Ozempic for diabetes can deny it. The diagnosis is the key that unlocks the door.
One more detail: since January 2025, Ozempic also has an FDA-approved use to lower the risk of worsening kidney disease and heart-related death in adults with type 2 diabetes and chronic kidney disease. If that's you, that diagnosis belongs on the request too.
What your doctor usually needs to submit for a diabetes GLP-1:
- Your type 2 diabetes diagnosis
- Recent labs (like your A1C)
- Which diabetes medicines you've already tried
- Why a “preferred” drug won't work for you (if one is required)
- Your state's prior authorization form
- The pharmacy rejection code, if you were already turned away
Does Medicaid cover GLP-1s for weight loss?
Sometimes — but not in most states. Federal law lets state Medicaid programs leave out drugs used for weight loss. KFF found only 13 state Medicaid fee-for-service programs covered GLP-1s for obesity as of January 2026 — down from 16 a year earlier.
Our 50-state tracker currently classifies 13 states as having an adult obesity GLP-1 coverage path and 37 states without one. By our estimate, only about 19.7% of adult Medicaid enrollees live in a state with that path — meaning roughly 80% live in states with no obesity GLP-1 coverage right now. The map is also moving fast:
Four states dropped adult weight-loss GLP-1 coverage effective January 1, 2026: California, New Hampshire, Pennsylvania, and South Carolina (KFF).
North Carolina dropped coverage, then brought it back in December 2025 (KFF).
Michigan tightened its rules so a GLP-1 for obesity alone is covered only if you're classified as morbidly obese, have already tried and failed other weight-loss treatments, and are using it to avoid weight-loss surgery. Virginia also added stricter criteria.
More states are debating cuts, including Massachusetts and Rhode Island (Stateline, April 2026).
California shows why “current” matters
California's Medi-Cal told members that, as of January 1, 2026, drugs like Wegovy, Zepbound, Saxenda, Ozempic, Rybelsus, Mounjaro, and Victoza are no longer covered for “weight loss only” for adults 21 and older — while some non-weight-loss uses may still have a path. Pennsylvania made a similar change the same day. The lesson: a static “list of states” you find online can be wrong within a month.
Updated monthly · shows current state status
One quick note: managed-care plans can differ from the state's main “fee-for-service” rules. If you're in a Medicaid health plan with its own name, its drug list may not match the state's exactly. Always confirm with your specific plan.
The path most people miss: getting covered through another condition
This is the section that changes outcomes.
Even where weight-loss-alone is excluded, Medicaid has to cover Wegovy for established heart disease and Zepbound for moderate-to-severe sleep apnea in every state — because those are separate FDA-approved uses. The requirement applies nationwide. You still need the right diagnosis documented and prior approval, but it's a real path that doesn't depend on whether your state covers “weight loss.”
Think of it like this. The door marked “weight loss” is locked in most states. But there are other doors — and the rule says they open everywhere.
Wegovy + heart disease
FDA approved Wegovy in March 2024 to lower the risk of heart attack, stroke, and heart-related death in adults who already have cardiovascular disease and are overweight or obese. If that's you, this is a different — and stronger — coverage conversation than weight loss.
Zepbound + sleep apnea
FDA approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. If you've had a sleep study showing apnea, ask about this path.
Wegovy + MASH (a serious liver disease)
FDA approved Wegovy in 2025 for adults with MASH and moderate-to-advanced liver scarring. If a specialist has documented this, it may be a covered use.
Diabetes
A covered path everywhere, as we covered above.
The catch is paperwork.
If your prior authorization gets submitted as “weight loss,” a plan that would say yes to “sleep apnea” or “heart disease” will say no. The diagnosis on the form decides the answer. So before you give up or pay cash, ask one question: “Was this submitted under the right diagnosis?” It's free to ask, and it's one of the highest-value moves on this entire page.
Turns your state, age, diagnosis, and drug into a clear next step
Drug-by-drug: which GLP-1 does Medicaid cover?
Does Medicaid cover Wegovy?
It depends on the reason. Medicaid may cover Wegovy three ways: for obesity (only in states that cover weight-loss GLP-1s), for heart-risk reduction in adults with established cardiovascular disease who are overweight or obese (a required path in every state when documented), and for MASH with moderate-to-advanced fibrosis. “Wegovy for weight loss only” is the path most likely to be denied.
• Wegovy for weight loss: state-optional. Check the 50-state tracker.
• Wegovy for heart disease: a separate, stronger path. FDA-approved March 2024.
• Wegovy for MASH: a separate path your liver specialist can document. FDA-approved 2025.
“Was Wegovy denied because my plan excludes weight-loss drugs, or because the prior authorization didn't include my diagnosis for heart disease, MASH, or another covered use?”
See our full Medicaid GLP-1 coverage guide for the complete Wegovy coverage picture.
Does Medicaid cover the Wegovy pill?
Same rules as the Wegovy injection — the diagnosis still drives it. The Wegovy pill (oral semaglutide) was FDA-approved in December 2025 as the first GLP-1 pill for weight management, and it's also approved to reduce heart-attack and stroke risk in adults with established cardiovascular disease who are overweight or obese. For Medicaid, obesity coverage is state-optional, the heart-risk path is stronger, and your plan still has to list the pill and its prior authorization rules.
Don't assume the pill and the injection are treated the same on your plan — sometimes one is listed and the other isn't.
Does Medicaid cover Zepbound?
Maybe for weight loss, and more reliably for sleep apnea. Medicaid may cover Zepbound for obesity only in states that cover weight-loss GLP-1s. But Zepbound also has an FDA-approved use for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024) — a required coverage path in every state when documented. If your request went in as weight loss only, ask whether your sleep apnea changes it.
What your prescriber may need for the sleep-apnea path:
- A sleep study with your AHI score (a number that measures apnea severity)
- The sleep apnea diagnosis, clearly coded
- Your obesity diagnosis and BMI
- Any past apnea treatment (like a CPAP machine)
Does Medicaid cover Ozempic or Mounjaro for weight loss?
Usually not when the goal is weight loss alone. Ozempic and Mounjaro are commonly covered by Medicaid for type 2 diabetes, but neither is FDA-approved for weight loss. Using a diabetes-labeled drug for weight loss without a covered diagnosis is a common reason for denial.
Does Medicaid cover Foundayo?
It's too new to assume. Foundayo (orforglipron) is an oral GLP-1 FDA-approved on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It's the second GLP-1 pill for weight loss, after the Wegovy pill — not the first. Because it's brand-new, your state's Medicaid drug list and prior authorization rules still decide coverage, and many plans may not list it clearly yet. Verify your state before relying on it.
Two things to keep straight:
Foundayo is orforglipron. The Wegovy pill is oral semaglutide. They are different medicines. Don't blur them. Foundayo's state-by-state Medicaid status isn't reliable enough yet to summarize nationally — check your plan's drug list and prior authorization criteria directly.
See our full guide on Medicaid coverage for Foundayo.
How do I check my own Medicaid plan without getting lost?
Start with your Medicaid card, not a search engine. Your card tells you whether you have “fee-for-service” Medicaid or a managed-care plan (a private plan that runs your Medicaid benefits). Then you check that exact plan's drug list, prior authorization form, and pharmacy phone number — because those are the only rules that apply to you.
Here's the step-by-step we'd follow:
- Look at your Medicaid card. Note the plan name.
- Figure out your plan type — fee-for-service, or a managed-care plan with its own name.
- Search your state or plan name + "preferred drug list GLP-1." This shows which GLP-1s are covered and preferred.
- Search your plan name + "prior authorization" + your drug (for example, "prior authorization Wegovy").
- Call the pharmacy benefits number on your card and use the script below.
- Bring it to your prescriber so they submit the request under the right diagnosis with the right records.
“I have Medicaid through [plan name]. Can you tell me whether [drug name] is covered for [diagnosis], whether prior authorization is required, and exactly what my prescriber needs to submit?”
Write down the answers — these five details decide everything:
| Write this down | Why it matters |
|---|---|
| Your plan name | Managed-care rules can differ from the state's main rules. |
| The drug name | Wegovy, Ozempic, Zepbound, and Mounjaro are not interchangeable for coverage. |
| The diagnosis | Coverage usually depends on the reason, not the drug. |
| Is prior authorization required? | Most GLP-1 approvals need a form and records. |
| The denial reason (if any) | The reason tells you your exact next move. |
What should my doctor submit for a GLP-1 prior authorization?
The right diagnosis, with records that match your plan's rules. The most common mistake is sending a broad “weight loss” request when your chart may hold a stronger, covered path — type 2 diabetes, heart disease, sleep apnea, MASH, or EPSDT medical necessity for a minor. Matching the request to the right use is often the difference between approved and denied.
Use this as a checklist with your prescriber. Each path needs different records:
| Coverage path | Records to ask your prescriber to include |
|---|---|
| Type 2 diabetes | Diagnosis, A1C/labs, past medicines, current regimen, preferred-drug history |
| Obesity only | BMI, weight history, past lifestyle/medicine attempts, your state's exact criteria |
| Heart disease + overweight/obesity | Cardiovascular diagnosis, BMI/weight, medicine history, the Wegovy heart-risk use |
| Sleep apnea + obesity | Sleep study/AHI, apnea diagnosis, BMI, CPAP history, the Zepbound sleep-apnea use |
| MASH | Liver diagnosis, fibrosis evidence, specialist notes, the Wegovy MASH use |
| Under 21 | EPSDT medical necessity, age, diagnosis, growth/weight history, specialist notes |
“Can we check whether my Medicaid plan covers [drug] for [diagnosis]? If prior authorization is needed, can the request include the diagnosis code, supporting labs or test results, my past medicines, and why this drug is medically necessary?”
What should I do if Medicaid denies my GLP-1?
First, get the denial reason in writing. A denial because your plan excludes weight-loss drugs is a completely different problem than a denial because a form was missing, the wrong diagnosis was used, or the records didn't meet the plan's rules. The reason tells you whether to fix-and-resubmit, switch the diagnosis path, or appeal.
Match your denial to its fix:
| Denial reason | What it likely means | Your next move |
|---|---|---|
| Weight-loss drugs excluded | Your plan/state doesn't cover obesity-only GLP-1s | Check if another covered use applies (diabetes, heart disease, sleep apnea); review the state tracker |
| Prior authorization missing | The pharmacy can't process it without your doctor's form | Ask your prescriber to submit the PA |
| Criteria not met | The records didn't satisfy the plan's rules | Ask exactly which requirement failed, then fill the gap |
| Non-preferred drug | The plan wants a different GLP-1 first | Ask which drug is preferred and whether you can try it |
| Diagnosis mismatch | It may have been submitted under the wrong reason | Ask your prescriber to correct and resubmit if appropriate |
| Age/benefit issue | Under-21 rules may differ | Ask about EPSDT if it's medically necessary |
“Please send me the denial letter and the exact reason. I want to know if it was denied for excluded weight-loss use, missing prior authorization, missing medical records, non-preferred drug status, or not meeting plan criteria — and how to appeal.”
Two more things: ask about your appeal deadline (miss it and the window can close), and don't assume a denial is the end. Plenty of denials are fixable paperwork or criteria gaps, not final answers.
Helps you build the questions for your prescriber, pharmacy, and plan before you appeal or switch paths
Can I use a coupon, GoodRx, or a savings card if I have Medicaid?
No — manufacturer savings cards exclude Medicaid members.
Drugmaker copay cards for GLP-1s like Wegovy, Zepbound, Ozempic, and Mounjaro specifically exclude anyone enrolled in Medicaid, Medicare, TRICARE, or VA. It's written into the card terms, and federal rules bar drugmakers from offering copay help to people in government programs like Medicaid. Discount cards like GoodRx may show a cash price, but they can't be combined with Medicaid.
Eli Lilly's Zepbound savings terms, for example, state you can't be enrolled in any state or federal healthcare program, including Medicaid. Novo Nordisk says the same for Wegovy.
What can a Medicaid member do if there's truly no covered path?
You can pay cash through the makers' own programs — these aren't billed to your Medicaid, so you can use them, but the price comes out of your pocket and won't count toward any Medicaid benefit. Here are the current self-pay prices, verified June 2026:
| Program | What it is | Self-pay price | Can a Medicaid member use it? |
|---|---|---|---|
| LillyDirect (Zepbound) | Lilly's direct pharmacy, brand Zepbound vials | $299/mo (2.5 mg), $399/mo (5 mg), $449/mo (7.5–15 mg) — the $449 rate needs a refill within 45 days, or the price rises (up to $499–$699) | Yes — cash-pay, not billed to Medicaid |
| NovoCare (Wegovy injection) | Novo's direct pharmacy, brand Wegovy | $199/mo for the first 2 months (lowest doses), then about $349/mo | Yes — cash-pay |
| NovoCare (Wegovy pill) | Brand oral semaglutide | About $149–$299/mo by dose | Yes — cash-pay |
| TrumpRx | Government-linked direct-purchase site | Oral options from about $149/mo; injectable Wegovy and Ozempic around $350/mo | Government insurance (including Medicaid) can't be applied — pay cash only |
Sources: Eli Lilly LillyDirect self-pay terms; Novo Nordisk announcements (Nov–Dec 2025); industry reporting. Verify current prices before you commit.
Source-verified pricing, FDA-approved and compounded clearly separated
What changed with Medicaid GLP-1 coverage in 2026?
Coverage is shifting because of cost — in both directions. Some states dropped adult obesity coverage to save money, while the federal government launched a voluntary program called BALANCE to negotiate lower GLP-1 prices and possibly expand access. BALANCE does not guarantee coverage for any one person.
The BALANCE Model
A voluntary CMS program meant to lower GLP-1 prices and widen access in Medicaid and Medicare. State Medicaid agencies can join starting in 2026. But it's optional, and coverage still depends on your state joining, the drugmaker participating, and you meeting prior authorization rules (CMS; KFF).
The BALANCE drug list
Includes all forms of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen form of Zepbound, and Foundayo — for their currently covered uses and for weight management. That's not the same as automatic coverage in your state (CMS).
Don't confuse Medicaid with the Medicare GLP-1 Bridge
The Bridge is a Medicare program (about $50 a month for Wegovy and the Zepbound KwikPen) for qualifying Medicare members. CMS extended it through December 31, 2027. If you're on Medicaid, the Bridge isn't your program. See our Medicare GLP-1 Bridge guide.
The takeaway: 2026 is a moving target. That's exactly why we put a “last verified” date on this page and re-check it on a schedule.
✅ What we actually verified for this guide — expand to see
| What we checked | Where it came from |
|---|---|
| Medicaid must cover diabetes GLP-1s; weight-loss coverage is state-optional | KFF + federal Medicaid Drug Rebate Program |
| Only 13 state fee-for-service programs covered obesity GLP-1s as of Jan 2026 (down from 16) | KFF + The RX Index state research |
| California, New Hampshire, Pennsylvania, South Carolina dropped adult weight-loss coverage Jan 1, 2026; North Carolina reinstated | KFF; state notices |
| Wegovy heart-disease use (March 2024) | FDA |
| Zepbound sleep apnea use (December 2024) | FDA |
| Wegovy MASH use (2025, accelerated approval) | FDA |
| Wegovy pill (oral semaglutide) approved Dec 2025; Foundayo (orforglipron) approved April 1, 2026 | FDA |
| Ozempic chronic-kidney-disease use (January 2025) | FDA |
| Byetta and Bydureon BCise discontinued in the U.S. (2024) | Manufacturer |
| Savings cards exclude Medicaid | Lilly (Zepbound) + Novo (Wegovy) program terms |
| Cash-pay prices (LillyDirect, NovoCare, TrumpRx) | Manufacturer pages + industry reporting |
| Medicare GLP-1 Bridge extended through Dec 31, 2027 | CMS; KFF |
| Ro does not serve Medicaid members | Ro's insurance page |
| Compounded drugs are not FDA-approved | FDA |
What we can't promise: Medicaid managed-care plans can differ from fee-for-service rules; state drug lists and forms change monthly; a covered drug can still be denied if the paperwork falls short; and we don't determine your eligibility — your plan, your prescriber, and your state agency do.
Real questions people are asking right now
You're not the only one trying to make sense of this. This whole guide is built to answer these:
- “Does Medicaid cover Ozempic if I'm not diabetic?”
- “Does having sleep apnea change whether Zepbound is covered?”
- “My prior authorization was denied — now what?”
- “Does PCOS count?”
- “Is Wegovy still covered in my state after the 2026 changes?”
Frequently asked questions
What GLP-1 does Medicaid cover?
Medicaid generally covers GLP-1s for type 2 diabetes in every state when plan rules are met, has required coverage paths for Wegovy in established heart disease or MASH and Zepbound in sleep apnea, and covers GLP-1s for weight loss only in the 13 states that chose to. The answer depends on the drug, your diagnosis, your state, your age, and your plan's prior authorization rules.
Does Medicaid cover Ozempic?
Medicaid commonly covers Ozempic for type 2 diabetes when plan rules are met. Ozempic for weight loss alone is a different request and is often denied if there's no covered diagnosis on file.
Does Medicaid cover Wegovy?
It depends on the reason. Wegovy for obesity is covered only in states that cover weight-loss GLP-1s. Wegovy also has FDA-approved uses for heart-risk reduction in adults with established cardiovascular disease and overweight or obesity, and for MASH with moderate-to-advanced fibrosis, both stronger coverage paths than weight loss alone, though prior authorization still applies.
Does Medicaid cover Zepbound?
Zepbound for obesity is covered only in states that cover weight-loss GLP-1s. Zepbound also has an FDA-approved use for moderate-to-severe obstructive sleep apnea in adults with obesity, which has a required coverage path in every state when the diagnosis and prior authorization are documented.
Does Medicaid cover Mounjaro?
Medicaid may cover Mounjaro for type 2 diabetes when plan rules are met. If your goal is weight loss, the tirzepatide brand approved for that is Zepbound, but obesity coverage depends on your state.
Does Medicaid cover the Wegovy pill?
The Wegovy pill (oral semaglutide) follows the same diagnosis-first logic as the injection: obesity coverage is state-optional and the heart-risk path is stronger. Your plan still has to list the pill and its prior authorization rules, and the pill and injection aren't always treated the same on a given plan.
Does Medicaid cover GLP-1s for PCOS?
Usually not for PCOS alone. Coverage typically depends on a covered diagnosis or your state's obesity-drug policy. Ask which diagnosis is being used for your request.
Does Medicaid cover GLP-1s for prediabetes?
Prediabetes alone often isn't enough for coverage. Ask your prescriber and plan what diagnosis is being used and whether another covered use applies.
Can someone under 21 get Wegovy or Zepbound through Medicaid?
Possibly. Medicaid's EPSDT benefit can require coverage when treatment is medically necessary for children and teens, but the prescriber must document medical necessity and follow the state process.
Does Medicaid pay for compounded semaglutide or tirzepatide?
Generally no. The FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before they're sold, so they are not a standard Medicaid coverage path.
Can I use a savings card or coupon if I have Medicaid?
No. Manufacturer savings cards exclude people enrolled in Medicaid and other government programs. Cash-pay programs like LillyDirect are allowed because they aren't billed to your plan, but you pay full price out of pocket.
Will the CMS BALANCE program make Medicaid cover GLP-1s in every state?
No. CMS says Medicaid participation in BALANCE is voluntary, and coverage depends on your state and the drugmaker joining, plus eligibility and prior authorization rules.
Still not sure?
You've got the map now — the drug, the diagnosis, the state, the paperwork. The last step is making it personal to your situation so you walk into your next appointment certain instead of guessing.
Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz →By The RX Index Editorial Team. Last verified: June 2026. We built this guide from CMS and FDA sources, KFF's Medicaid GLP-1 analysis, state Medicaid notices, and manufacturer program terms, cross-linked with The RX Index's 50-state Medicaid coverage research. It's educational coverage guidance only and does not replace advice from your clinician, pharmacist, Medicaid plan, or state Medicaid agency.
Sources — expand to see
- KFF — Medicaid Coverage of and Spending on GLP-1s (Jan 2026): kff.org/medicaid/
- KFF — What to Know About the BALANCE Model and the Medicare GLP-1 Bridge (updated May 2026): kff.org/medicare/
- CMS — BALANCE Model: cms.gov/priorities/innovation/
- FDA — Wegovy approved to reduce serious heart problems in adults with obesity/overweight (Mar 2024)
- FDA — Zepbound approved for obstructive sleep apnea (Dec 2024)
- FDA — Wegovy approved for MASH (2025)
- FDA / Novo Nordisk — Wegovy pill (oral semaglutide) approval (Dec 22, 2025)
- FDA — Foundayo (orforglipron) approval (Apr 1, 2026)
- FDA / Novo Nordisk — Ozempic approved for chronic kidney disease in type 2 diabetes (Jan 28, 2025)
- FDA — Compounding and the FDA: Questions and Answers
- Eli Lilly — Zepbound savings terms (Medicaid/government exclusion): zepbound.lilly.com/savings
- Novo Nordisk — Wegovy savings/self-pay eligibility: novocare.com
- Stateline — More states consider dropping GLP-1 weight-loss drugs from Medicaid (Apr 2026)
- California Medi-Cal Rx — Changes to GLP-1 Drug Coverage, effective Jan. 1, 2026
- Ro — Weight Loss Program and Insurance (Medicaid not eligible): ro.co/weight-loss/insurance/
- The RX Index — GLP-1 Medicaid Coverage by State (2026)
Related guides
The RX Index is an independent editorial publisher. We score GLP-1 providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost. We are not affiliated with Eli Lilly, Novo Nordisk, or any drug manufacturer. Some links may earn a commission.